RxDoctor Payments Data

Mohiman Saffar, MD

Family Medicine · Novi, MINPI 1952838138

Payments from drug & device makers

$1,578in general payments, 2019–2025

Across 68 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$398
  • Novo Nordisk$273
  • Exact Sciences$194
  • Lilly USA, LLC$154
  • Pfizer$135
  • Sanofi Pasteur Inc.$125
  • plus $299 from 10 others

What the payments were for

  • Food & beverage$1,578100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,578 in reported general payments places this provider in the 75th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$57,604
Medicare patients
189
Services billed
599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$60,789
JardianceEmpagliflozin27$39,811
JanuviaSitagliptin Phosphate28$33,122
MounjaroTirzepatide29$30,051
OzempicSemaglutide18$28,689
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,929
AbrysvoRsv Vacc, Pref A And Pref B/Pf25$7,982
Atorvastatin Calcium248$3,108
Levothyroxine Sodium178$2,443
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,323
Lisinopril253$2,139
Albuterol Sulfate HfaAlbuterol Sulfate56$2,037
Metoprolol Succinate99$1,846
Rosuvastatin Calcium85$1,777
Amlodipine Besylate221$1,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo, Paxlovid$135$70,052118 claims
Boehringer IngelheimJardiance$23$39,81127 claims
Lilly USA, LLCMounjaro$154$30,05129 claims
Novo NordiskOzempic$273$28,68918 claims
GSKTrelegy Ellipta$52$8,92912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Novi

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →